Vectura Group has confirmed that its US partner for the VR315 fluticasone/salmeterol DPI and the VR506 generic fluticasone propionate DPI is Boehringer Ingelheim subsidiary Roxane Laboratories. The company is partnered with Sandoz on VR315 in the rest of the world.
When Vectura announced the VR315 US licensing deal in August 2011, it referred to its partner as “a US division of an undisclosed leading international pharmaceutical company.” In June 2014, the company announced that the partnership had been expanded to include VR506.
Vectura also announced that a bioequivalence study comparing VR315 to Advair Diskus has been completed. CEO James Ward-Lilley commented, “This announcement marks an important step in the progression to market for our VR315 program. With the completion of this important clinical trial and details of the study and partner disclosed we now look forward to submission of the file, positioning VR315 competitively in what will be a major value opportunity.”
Roxane has already paid $12 million in development milestones for VR315, and the deal includes an additional $32 million in potential milestone payments. For VR506, Vectura has received a $4 million milestone payment and is eligible for another $8 million.
Read the Vectura press release.
